Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - raltegravir potassium 108.6 mg eqv raltegravir - tablet, chewable - 100 mg - raltegravir potassium 108.6 mg eqv raltegravir 100 mg

Singapore - English - HSA (Health Sciences Authority)

viatris private limited - phenytoin sodium - capsule - 100 mg - phenytoin sodium 100 mg

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - bortezomib - multiple myeloma - antineoplastic agents - bortezomib accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.bortezomib accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.bortezomib accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

European Union - English - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonavir - hiv infections - antivirals for systemic use, - ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv-1-infected patients (adults and children of two years of age and older).,

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - voriconazole - aspergillosis; candidiasis; mycoses - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole accord should be administered primarily to patients with progressive, possibly life-threatening infections.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - palonosetron - vomiting; nausea; cancer - antiemetics and antinauseants, - palonosetron accord is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.palonosetron accord is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - sodium valproate 100 mg/ml - solution for injection - 100 mg/ml - active: sodium valproate 100 mg/ml excipient: dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate phosphoric acid sodium hydroxide water for injection - the treatment of patients with epilepsy or bipolar disorder, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Canada - English - Health Canada

abbvie corporation - ritonavir - capsule - 100mg - ritonavir 100mg - hiv protease inhibitors

United States - English - NLM (National Library of Medicine)

abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ritonavir 100 mg - norvir tablets and oral solution are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. norvir oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with hiv-1 infection. - when co-administering norvir with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information. - norvir is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (ten) or stevens-johnson syndrome) to ritonavir or any of its ingredients. - norvir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions ( 7.1 ) and clinical pharmacology ( 12.3 )] . ○ alpha 1- adrenoreceptor antagonist : alfuzosin ○ antianginal: ranolazine ○ antiarrhythmics: amiodarone, dronedarone, flecainide, propaf